In cancer research, long non‑coding RNAs (lncRNAs) are emerging as critical regulators of tumorigenesis. The Cancer LncRNome Atlas (TCLA) offers a robust platform to explore how lncRNAs are altered across diverse cancer types—including expression, genomic… What TCLA Reveals About lncRNA Alterations In Cancer Research
Modern cancer treatment is rapidly evolving—thanks in part to discoveries in the long non‑coding RNA (lncRNA) domain. The Functional Cancer Genome (FCG) Portal enables researchers to examine lncRNA transcriptional, genomic, and epigenetic alterations across cancers,… How lncRNA Insights From FCG Could Drive Cancer Treatment
Cancer is notoriously complex, arising from intricate interactions across multiple molecular layers. The Functional Cancer Genome (FCG) Portal offers a groundbreaking integrated omics platform by melding genomics, functionomics, and pharmacologenomics—empowering researchers to unravel the molecular… The Power Of Integrated Omics Via FCG’s Cancer Portal
The nuclear receptor superfamily comprises 48 ligand-activated transcription factors that regulate a myriad of physiological processes, including metabolism, development, and immune responses. In the context of cancer, these receptors influence tumor initiation, progression, and response to therapies.… Exploring the Nuclear Receptor Superfamily in Cancer via FCG
Cancer remains one of the most formidable challenges in modern medicine, with treatment resistance and relapse posing significant hurdles. Recent research highlights the potential of combining Bromodomain and Extra-Terminal (BET) protein inhibition with Poly(ADP-ribose) polymerase (PARP) inhibitors to enhance… How BET Repression and PARP Inhibition Can Combat Cancer—Data from FCG